Cellect Biotechnology Ltd. and Washington University (WU) announced the signing of an Accelerated Clinical Trial Agreement (CTA). Cellect has successfully completed the technology transfer to WU's facility, and results of the in-vivo portion of the toxicology study have shown no signs or symptoms of toxicity. The ongoing and positive discussions with the U.S. Food and Drug Administration (FDA), and based on its feedback the company can bypass further pre-Investigation New Drug (IND) interactions and proceed directly to IND filing. Therefore, the company's immediate next step is to complete IND application and submit it to the FDA during the third quarter, and objective remains to commence treatment of U.S. patients during the first half of 2020.